JP2017530108A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530108A5
JP2017530108A5 JP2017512822A JP2017512822A JP2017530108A5 JP 2017530108 A5 JP2017530108 A5 JP 2017530108A5 JP 2017512822 A JP2017512822 A JP 2017512822A JP 2017512822 A JP2017512822 A JP 2017512822A JP 2017530108 A5 JP2017530108 A5 JP 2017530108A5
Authority
JP
Japan
Prior art keywords
place
oeg
mimiline
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512822A
Other languages
English (en)
Japanese (ja)
Other versions
JP6728141B2 (ja
JP2017530108A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/069996 external-priority patent/WO2016034604A1/en
Publication of JP2017530108A publication Critical patent/JP2017530108A/ja
Publication of JP2017530108A5 publication Critical patent/JP2017530108A5/ja
Application granted granted Critical
Publication of JP6728141B2 publication Critical patent/JP6728141B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512822A 2014-09-04 2015-09-02 新規のアミリン及びカルシトニン受容体アゴニスト Active JP6728141B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14183551.2 2014-09-04
EP14183551 2014-09-04
PCT/EP2015/069996 WO2016034604A1 (en) 2014-09-04 2015-09-02 Novel amylin and calcitonin receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020114038A Division JP7095027B2 (ja) 2014-09-04 2020-07-01 新規のアミリン及びカルシトニン受容体アゴニスト

Publications (3)

Publication Number Publication Date
JP2017530108A JP2017530108A (ja) 2017-10-12
JP2017530108A5 true JP2017530108A5 (enExample) 2018-10-11
JP6728141B2 JP6728141B2 (ja) 2020-07-22

Family

ID=51483301

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512822A Active JP6728141B2 (ja) 2014-09-04 2015-09-02 新規のアミリン及びカルシトニン受容体アゴニスト
JP2020114038A Active JP7095027B2 (ja) 2014-09-04 2020-07-01 新規のアミリン及びカルシトニン受容体アゴニスト
JP2022100480A Pending JP2022130522A (ja) 2014-09-04 2022-06-22 新規のアミリン及びカルシトニン受容体アゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020114038A Active JP7095027B2 (ja) 2014-09-04 2020-07-01 新規のアミリン及びカルシトニン受容体アゴニスト
JP2022100480A Pending JP2022130522A (ja) 2014-09-04 2022-06-22 新規のアミリン及びカルシトニン受容体アゴニスト

Country Status (8)

Country Link
US (2) US9593149B2 (enExample)
EP (1) EP3189071B1 (enExample)
JP (3) JP6728141B2 (enExample)
CN (1) CN106687474A (enExample)
AR (1) AR101742A1 (enExample)
ES (1) ES2887370T3 (enExample)
TW (1) TW201625671A (enExample)
WO (1) WO2016034604A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107567459B (zh) 2015-03-18 2021-09-24 西兰制药公司 胰淀素类似物
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
US11274158B2 (en) 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
AU2019357621B2 (en) 2018-10-11 2025-04-03 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
TW202440619A (zh) * 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
TWI790850B (zh) * 2020-12-18 2023-01-21 美商美國禮來大藥廠 雙重澱粉素及降鈣素受體促效劑及其用途
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
IL312672A (en) * 2021-11-10 2024-07-01 I2O Therapeutics Inc Ionic liquid compositions
CN116621944A (zh) * 2022-02-10 2023-08-22 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂
JP2025530743A (ja) 2022-08-29 2025-09-17 イーライ リリー アンド カンパニー 経口投与のための組成物
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
KR20250083391A (ko) 2023-11-30 2025-06-10 노보 노르디스크 에이/에스 Glp-1, gip, 및 아밀린 수용체의 삼중작용제
WO2025240893A1 (en) 2024-05-17 2025-11-20 Eli Lilly And Company 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US4659804A (en) 1984-11-01 1987-04-21 Armour Pharmaceutical Company (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin
US4622386A (en) * 1985-03-28 1986-11-11 Armour Pharmaceutical Company [1,7-di-alanine]calcitonin
EP0297159A1 (en) * 1987-07-01 1989-01-04 Armour Pharmaceutical Company [N-Acyl, 1,7-Di-Aline] calcitonins, method for their preparation, pharmaceutical compositions and use
US5153308A (en) 1988-06-16 1992-10-06 Teijin Limited S-sulfonated calcitonin derivatives
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
CN1064051C (zh) 1997-04-30 2001-04-04 中国人民解放军军事医学科学院毒物药物研究所 不含二硫键的鲑鱼和鳗鱼降钙素类似物及其制备方法
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2007014051A2 (en) 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
WO2009156473A1 (en) * 2008-06-25 2009-12-30 Novo Nordisk A/S Derivatised hybrid peptides of amylin and salmon calcitonin
JP5753097B2 (ja) * 2009-01-22 2015-07-22 ユニジーン・ラボラトリーズ・インコーポレーテッド 肥満の治療
CA2755068C (en) * 2009-03-12 2018-11-06 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
CA2813087C (en) * 2010-09-28 2020-07-21 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
SG194998A1 (en) * 2011-05-25 2013-12-30 Amylin Pharmaceuticals Llc Amylin peptides and derivatives and uses thereof
CN103596973A (zh) * 2011-06-10 2014-02-19 诺沃—诺迪斯克有限公司 多肽

Similar Documents

Publication Publication Date Title
JP2017530108A5 (enExample)
JP2015514395A5 (enExample)
NZ740644A (en) Glucagon receptor agonists
JP2014525439A5 (enExample)
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
MX2017004559A (es) Receptores de celulas t.
JP2014224126A5 (enExample)
JP2014501510A5 (enExample)
NZ715038A (en) T cell receptors
JP2007045829A5 (enExample)
JP2017528419A5 (enExample)
MX2017016101A (es) Polinucleotidos y polipetidos de adenovirus.
EA200870237A1 (ru) Последовательности пептидов и композиции
JP2010065037A5 (enExample)
JP2015516983A5 (enExample)
ES2531288T3 (es) Proteína de fusión anticancerígena
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2016002891A (es) Virus recombinantes de la enfermedad de marek y usos de los mismos.
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
PH12019550241A1 (en) Mic-1 compounds and uses thereof
JP2014058541A5 (enExample)
WO2015107363A3 (en) Mycobacterial antigen composition
JP2010532766A5 (enExample)
JP2017505772A5 (enExample)
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso